ArticleFolia microbiologica2026
Unveiling multifaceted antimicrobial effect of epicatechin: from bacteria to filamentous fungi and beyond.
Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the biological properties of epicatechin, a polyphenolic compound widely distributed in green tea, grapes, various berry species, and other dietary matrices, examining its effects on bacteria, filamentous fungi, and the in vivo model Galleria mellonella. Epicatechin proved inhibitory activity against both model bacterial strains and clinical or environmental isolates. Specifically, it was effective against Staphylococcus strains by inhibiting their growth, and against Gram-negative bacteria by preventing biofilm formation. Furthermore, epicatechin increased the susceptibility of MRSA (methicillin-resistant Staphylococcus aureus) to several antibiotics, including cefoxitin, gentamicin, and tetracycline. The in vivo experiments using Galleria mellonella larvae infected with MRSA and treated with high doses of epicatechin displayed an increase in larval survival during the initial 24 h post-infection. Epicatechin exhibited no inhibitory activity against pathogenic yeasts and most of tested filamentous fungi. However, its effect was well pronounced in Neurospora crassa. In this specific case, epicatechin enhanced the efficacy of echinocandins and azoles. The safety profile of epicatechin was confirmed by the Ames test and in vivo toxicity assessments using Galleria mellonella, both indicating that epicatechin is non-mutagenic and non-toxic. These findings highlight the potential of epicatechin, particularly in antimicrobial and antifungal applications.
Indexed as
Identifiers
41893921What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.